Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

John G. Gribben, Paola Ghione, Maria Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Olga Nikolajeva, Jiali Yan, Hailin Wang, Anik R Patel

Blood (2023) 142 (Supplement 1): 4869.

https://doi.org/10.1182/blood-2023-186842

Published: 2023

Journal Articles

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

John G. Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien, Lewis Kopenhafer, Flor Mendez, Sara Beygi, Timothy Best, Graeme Ball, Kacper Perkowski, Patrick Olsen, Anik R Patel, Paola Ghione

Blood (2023) 142 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2023-190261

Published: 2023

Journal Articles

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Anik R Patel, Mark Ray, Yael A Rodriguez-Guadarrama, Nathaniel J Smith, Frank Neumann, Rob Blisset, Allen Xiaodong Xue

Blood (2023) 142 (Supplement 1): 6899.

https://doi.org/10.1182/blood-2023-181255

Published: 2023

Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US

Olalekan O. Oluwole, Markqayne D Ray, Richard Zur, Aurelia Little, Cheryl Ferrufino, Brett Doble, Anik R Patel, Pinar Bilir

Blood (2023) 142 (Supplement 1): 5082.

https://doi.org/10.1182/blood-2023-186548

Published: 2023

Journal Articles

Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Frederick L. Locke, Sattva S. Neelapu, Markqayne D. Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R. Patel, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 7516–7518.

https://doi.org/10.1182/blood-2022-169812

Published: 2022

Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini

Blood (2022) 140 (Supplement 1): 7512–7515.

https://doi.org/10.1182/blood-2022-155603

Published: 2022

Journal Articles

Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, Pinar Bilir, Anik R. Patel, Caron A. Jacobson

Blood (2022) 140 (Supplement 1): 10822–10824.

https://doi.org/10.1182/blood-2022-163789

Published: 2022

Journal Articles

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Paola Ghione, Maria Lia Palomba, Markqayne D. Ray, Eve H. Limbrick-Oldfield, Jess Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribeiro, Caron A. Jacobson, Sattva S. Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R. Patel, John G. Gribben

Blood (2022) 140 (Supplement 1): 4676–4677.

https://doi.org/10.1182/blood-2022-170469

Published: 2022

Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood (2022) 140 (Supplement 1): 1852–1855.

https://doi.org/10.1182/blood-2022-162421

Published: 2022

Journal Articles

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Paola Ghione, M. Lia Palomba, Anik R. Patel, Sabela Bobillo, Kevin Deighton, Caron A. Jacobson, Myrna Nahas, Anthony J. Hatswell, A. Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Ribeiro, M. Alan Brookhart, Herve Ghesquieres, John Radford, John G. Gribben

Blood (2022) 140 (8): 851–860.

https://doi.org/10.1182/blood.2021014375

Published: 2022

Includes: Supplemental data

Journal Articles

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

M. Lia Palomba, Paola Ghione, Anik R. Patel, Kevin Deighton, Caron Jacobson, Myrna Nahas, A Scott Jung, Anthony J Hatswell, Steve Kanters, Eve Limbrick-Oldfield, Sally W Wade, Julia Thornton Snider, Sattva S. Neelapu, Maria Teresa Riberio, John Gribben, John Radford, Sabela Bobillo, Herve Ghesquieres

Blood (2021) 138 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2021-147608

Published: 2021

Journal Articles

Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review

Brad S. Kahl, MD, Anik R. Patel, PhD, Omer Zaidi, Sonya J. Snedecor, PhD, Anna G. Purdum, PharmD,MS

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136228

Published: 2020

NARROW

An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Cost-Effectiveness of Axicabtagene Ciloleucel Versus Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma in the US

Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only